It's the second time in two years that rumors about Fosun Chairman Guo Guangchang's whereabouts stirred the market.
Transparency hasn't made much of a difference when it comes to drug and device makers' payments to doctors, which amounted to $2.6 billion last year.
CAR-T and TCR therapies have seen a whirlwind few years. Is 2017 set to be the year we see a CAR-T therapy approved? On a mission to find out, we sat down with…
On Friday, Bayer announced it’d be lowering its earnings forecasts with its second-quarter earnings release—and that consumer health was, in part, to blame.
Eli Lilly has won a nod from NICE for its anticipated blockbuster and Humira competitor, Olumiant, a drug the FDA rejected in April.
With the expanding definition of “health” in play, does the category warrant a separate show in a program like the Lions?
Weeks after announcing a €5.32 billion ($5.63 billion) buyout, German generics maker Stada said the deal failed to get shareholder approval.
The European Medicines Agency today recommended approval of Imraldi, a Humira biosimilar from Samsung and Biogen.
A shareholder campaign demanding change at Mylan has come up short.
Russia is pushing back on an issue that has raised concerns around the world: cancer drug prices.
Shire nabbed FDA approval Wednesday for its new long-acting ADHD drug Mydayis, and it's targeting $500 million in sales by 2020.
Mylan, which already has a low tax rate by being based in the Netherlands, has cut it into the single digits by investing in refined coal plants.